Use of il-22 for the treatment of conditions of metabolic disorders

Abstract

The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetics. IL-22 may also be used in combination with insulin for diabetics.

1 . A method of treating a metabolic disorder, or a medical condition or disease associated therewith, comprising administering to a subject in need thereof a therapeutically effective amount of a polypeptide consisting essentially of IL-22 or a known functional derivative thereof. 
     
     
         2 . The method according to  claim 1 , wherein the metabolic disorder or medical condition or disease comprises obesity, diabetes, hyperlipidemia, hyperglycemia or hyperinsulinemia. 
     
     
         3 . The method according to  claim 1 , further comprising administering a therapeutically effective amount of insulin or a known functional derivative thereof. 
     
     
         4 . The method according to  claim 1 , wherein the polypeptide consisting essentially of IL-22 is provided with, and expressed by, a pharmaceutically acceptable and therapeutically effective expression system. 
     
     
         5 . The method according to  claim 4 , wherein the expression system synthesizes an in vivo effective amount of the polypeptide consisting essentially of IL-22. 
     
     
         6 . The method according to  claim 1 , wherein the polypeptide consists essentially of human IL-22 or mouse IL-22. 
     
     
         7 . A method of reducing body weight in a subject, said method comprising administering to sadi subject an effective amount of IL-22. 
     
     
         8 . Use of IL-22 or functional derivatives thereof for the manufacture of a medicament for the treatment of metabolic disorders. 
     
     
         9 . Use of IL-22 for the manufacture of a medicament for the treatment of maetabolic disorders. 
     
     
         10 . The use according to  claim 9  wherein said metabolic disorder comprises a condition selected form a group consisting of obesity. diabetes, hyperlipidemia, hyperglycemia and hyperinsulinemia. 
     
     
         11 . Use of IL-22 or functional derivatives thereof for the manufacture of a medicament for the reduction of body weight. 
     
     
         12 . Use of IL-22 for the manufacture of a medicament for the reduction of body weight. 
     
     
         13 . Use a combination of IL-22 and insulin for the treatment of blood glucose disorders. 
     
     
         14 . A method of treating a metabolic disorder, or medical condition or disease associated therewith, comprising
 delivering to a subject in need of treatment a polynucleotide comprising a DNA that encodes a polypeptide consisting essentially of IL-22 delivery system;   providing an expression system for the polypeptide encoding DNA; and   allowing the in vivo expression of a therapeutic amount of the polypeptide.   
     
     
         15 . The method of  claim 14 , wherein the metabolic disorder or medical condition or disease comprises or is associated with obesity, diabetes, hyperlipidemia, hyperglycemia or hyperinsulinemia. 
     
     
         16 . The method of  claim 14 , wherein the gene delivery system comprises at least one of a retroviral vector(s), adenoviral vector(s), or liposome-mediated director plasmid delivery, or receptor-mediated gene delivery. 
     
     
         17 . The method of  claim 14 , which comprises gene therapy alone, or in combination with another known therapy(ies). 
     
     
         18 . The method of  claim 14 , further comprising administering a therapeutically effective amount of insulin or a known functional derivative thereof. 
     
     
         19 . The method of  claim 14 , wherein the expression system synthesizes an in vivo effective amount of the polypeptide consisting essentially of IL-22. 
     
     
         20 . The method of  claim 14 , wherein the polypeptide consists essentially of human IL-22 or mouse IL-22.